NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The on-demand presentation will be available starting January 11 at 6:00 a.m. ET and can be accessed on NeuBase's website. NeuBase is focused on accelerating the genetic revolution with its synthetic medicines aimed at treating genetic diseases through its proprietary PATrOL™ therapies, targeting neurological, neuromuscular, and oncologic disorders.
Details
News Market Reaction – NBSE
The recorded move for NBSE in the trading session of this news was -1.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Jan. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview during the H.C. Wainwright Virtual BioConnect Conference, which is being held from January 11 - 14, 2021. A webcast of the on-demand presentation will be available beginning today at 6:00 a.m. Eastern Time and archived on the NeuBase website, www.neubasetherapeutics.com.
About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576
NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.